Trials / Completed
CompletedNCT04555213
A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19
A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Noxopharm Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase Ib, open-label, multicenter, study of NOX66, given rectally to hospitalized patients with moderate systemic illness due to COVID-19 infection at high risk of developing severe sepsis / septic shock.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NOX66 | NOX66 Suppository |
Timeline
- Start date
- 2020-09-30
- Primary completion
- 2021-08-10
- Completion
- 2021-08-10
- First posted
- 2020-09-18
- Last updated
- 2021-08-26
Locations
1 site across 1 country: Moldova
Source: ClinicalTrials.gov record NCT04555213. Inclusion in this directory is not an endorsement.